| Bioactivity | ACH-806 is an NS4A antagonist which can inhibit Hepatitis C Virus (HCV) replication with an EC50 of 14 nM. |
| Target | NS4AEC50: 14 nM (HCV) |
| Invitro | ACH-806 is an NS4A antagonist which can inhibit Hepatitis C Virus (HCV) replication with an EC50 of 14 nM. ACH-806 treatment results in significant reductions of both NS3 and NS4A in the transfected cells. This finding is reminiscent of ACH-806-treated replicon cells in which the amounts of NS3 and NS4A are also both decreased. The total amount of NS3 in the ACH-806-treated sample is reduced by ~6-fold (100/16) and causes a reduction of NS4A-bound NS3 ~29-fold (261/9). The levels of labeled NS3 and NS4A immunoprecipitated by anti-NS3 antibody are apparently reduced after the treatment of ACH-806. ACH-806 also induces significant decreases of NS3 and NS4A and promotes p14 formation in the parental replicon cells but not in the ACH-806-resistant replicon cells[1]. |
| Name | ACH-806 |
| CAS | 870142-71-5 |
| Formula | C19H20F3N3O2S |
| Molar Mass | 411.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yang W, et al. ACH-806, an NS4A antagonist, inhibits hepatitis C virus replication by altering the composition of viral replication complexes. Antimicrob Agents Chemother. 2013 Jul;57(7):3168-77. |